Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) have been given a consensus recommendation of “Hold” by the seven analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $112.33.

A number of research analysts recently commented on the company. Zacks Investment Research cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 12th. Wolfe Research assumed coverage on Enanta Pharmaceuticals in a report on Friday, May 24th. They issued an “outperform” rating and a $117.00 price objective on the stock. Finally, BidaskClub cut Enanta Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 10th.

ENTA traded up $0.24 during trading hours on Thursday, reaching $70.94. The company’s stock had a trading volume of 1,056 shares, compared to its average volume of 170,481. Enanta Pharmaceuticals has a fifty-two week low of $63.37 and a fifty-two week high of $106.80. The stock has a market cap of $1.39 billion, a PE ratio of 20.50 and a beta of 0.97. The business’s 50-day moving average is $70.80 and its 200-day moving average is $85.61.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.33 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.27. Enanta Pharmaceuticals had a return on equity of 15.16% and a net margin of 29.22%. The firm had revenue of $44.40 million for the quarter, compared to analysts’ expectations of $46.98 million. During the same period in the prior year, the firm posted $0.97 earnings per share. The firm’s quarterly revenue was down 22.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Enanta Pharmaceuticals will post 2.47 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. Dupont Capital Management Corp lifted its stake in Enanta Pharmaceuticals by 9.5% during the second quarter. Dupont Capital Management Corp now owns 13,477 shares of the biotechnology company’s stock worth $1,137,000 after purchasing an additional 1,174 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Enanta Pharmaceuticals in the second quarter valued at $224,000. THB Asset Management purchased a new position in Enanta Pharmaceuticals in the first quarter valued at $341,000. Russell Investments Group Ltd. increased its holdings in Enanta Pharmaceuticals by 2.2% in the second quarter. Russell Investments Group Ltd. now owns 89,505 shares of the biotechnology company’s stock valued at $7,515,000 after buying an additional 1,890 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in Enanta Pharmaceuticals by 8.1% in the second quarter. Janus Henderson Group PLC now owns 944,787 shares of the biotechnology company’s stock valued at $79,721,000 after buying an additional 70,390 shares during the last quarter. Institutional investors own 88.57% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: Momentum Investing

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.